Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Non-Squamous NSCLC Patients Previously Treated With Platinum-Based Chemotherapy in Combination With a Checkpoint Inhibitor

Condition:   Non-Squamous Non-Small Cell Lung Cancer Interventions:   Biological: Nivolumab;   Drug: Sitravatinib;   Drug: Docetaxel Sponsors:   Mirati Therapeutics Inc.;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials